Thermo Fisher Scientific Inc.
Analysis
Thermo Fisher's growth has turned. Organic revenue went from roughly flat in early 2025 to 5% in Q2 FY2026, and for the first time in this stretch all four end markets grew together. Guidance has been raised three quarters running. How did bioprocessing peers grow versus Thermo's bioproduction in Q2?
- The recovery is finally broad, not just one or two markets.
In Q2 FY2026 all four end markets grew at once, with academic and government back in growth and China positive again after a year of declines. Management now expects to land at the top of its organic growth range rather than the bottom. Which end market drove most of Thermo's Q2 organic growth?
- Bioproduction and clinical research are carrying the growth.
Bioproduction keeps growing faster than peers, helped by the filtration business bought from Solventum. Clinical research stepped up to mid-single digits as biotech funding converts into spending, about six months after it is raised. How much of Thermo's clinical research backlog converts to revenue this year?
- Costs are arriving faster than the recovery.
Tariffs and currency swings have cut more than a percentage point from margin four quarters running, and management has set aside money for inflation it has not yet shown it can offset. Deals like Clario weigh on profit in year one.
- Biotech funding recoveryThe bull case is that biotech funding has turned and customer spending is converting into orders, so pharma and biotech revenue can keep building from here.
- Bioproduction share gainsBioproduction is growing faster than competitors report, and reshoring of drug production should add equipment and consumable demand as new U.S. plants are built.
- Services and clinical researchClinical research authorizations, the Accelerator offering and the Clario purchase give Thermo Fisher a services franchise that customers rarely split among several suppliers.
- Academic funding not normalThe bear case is that U.S. academic and government spending stays below normal and instrument sales never return to prior levels even after the federal budget passes.
- Back-half pharma servicesA large share of expected growth sits in the second half, tied to pharma services production schedules that can slip if customer campaigns move.
- Tariffs and inflationTariffs, a stronger dollar and oil-driven cost inflation can hit margins faster than the company's productivity programs remove the cost.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Sale | ≥$1K | Jun 23 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$250K | Jun 18 | Aug 22 |
Donald Trump Republican · Executive | Purchase | ≥$1K | May 18 | Jul 1 |
Donald Trump Republican · Executive | Purchase | ≥$15K | Mar 25 | May 13 |
Donald Trump Republican · Executive | Sale | ≥$50K | Mar 18 | May 13 |
Congressional trading data provided by QuiverQuant
How Thermo Fisher Scientific turned $44.6B of revenue into $7.7B of operating income.
| Revenue | ||
|---|---|---|
| Consumables | $18.7B | ▲ 6.12% YoY |
| Service | $18.6B | ▲ 4.19% YoY |
| Instruments | $7.3B | ▼ 1.95% YoY |
| Total revenue | $44.6B | |
| Gross profit | $18.2B | 40.9% |
| Operating income | $7.7B | 17.4% |